Update on genetic screening and treatment for infertile men with genetic disorders in the era of assisted reproductive technology

Seung Ryeol Lee1, Tae Ho Lee2, Seung-Hun Song2, Dong Suk Kim2, Kyung Hwa Choi1, Jae Ho Lee3, Dae Keun Kim4

1 Department of Urology, CHA Bundang Medical Center, CHA University, Seongnam; 2 Department of Urology, Fertility Center, CHA Gangnam Medical Center, CHA University, Seoul, Korea; 3 Department of Biomedical Science, College of Life Science, CHA University, Pocheon; 4 Department of Urology, CHA Fertility Center Seoul Station, CHA University School of Medicine, Seoul, Korea

A genetic etiology of male infertility is identified in fewer than 25% of infertile men, while 30% of infertile men lack a clear etiology, resulting in a diagnosis of idiopathic male infertility. Advances in reproductive genetics have provided insights into the mechanisms of male infertility, and a characterization of the genetic basis of male infertility may have broad implications for understanding the causes of infertility and determining the prognosis, optimal treatment, and management of couples. In a substantial proportion of patients with azoospermia, known genetic factors contribute to male infertility. Additionally, the number of identified genetic anomalies in other etiologies of male infertility is growing through advances in whole-genome amplification and next-generation sequencing. In this review, we present an up-to-date overview of the indications for appropriate genetic tests, summarize the characteristics of chromosomal and genetic diseases, and discuss the treatment of couples with genetic infertility by microdissection-testicular sperm extraction, personalized hormone therapy, and in vitro fertilization with pre-implantation genetic testing.

Keywords: Azoospermia; Genetics; Infertility; Spermatozoa

Introduction

More than 30% of cases of infertility are related to male factors alone, and male factors alone or in combination with female factors contribute to up to 50% of all cases of infertility among couples [1,2]. Male infertility is related to men’s overall health, and genetic abnormalities are thought to cause 13%–30% of cases of male infertility, with azoospermia being the most common phenotype associated with genetic abnormalities [3-5]. However, genetic analyses show no clear etiology of infertility in up to 72% of affected men, leading to a diagnosis of idiopathic male infertility [6].

Advancements in reproductive genetics have provided insights into the mechanisms of male infertility, and an important task in male reproductive medicine is to classify idiopathic male infertility based on its causes and elucidate the details of the pathogenesis of this condition. Based on recent progress in genome-analysis technologies, many genetic variations have been shown to be associated with male infertility [7]. Next-generation sequencing technologies have made particularly significant contributions to the search for candidate genes. Therefore, elucidation of the pathophysiology of male infertility through genetic approaches may contribute to increased pregnancy rates in the era of artificial reproductive technology.

Recently, the indications for genetic screening have been updated to achieve the best sensitivity and specificity from genetic tests. For the treatment of severe oligozoospermia and nonobstructive azoospermia (NOA) with genetic disease, hormone therapy or microdissection-testicular sperm extraction (m-TESE) is required. Following rapid technological advances in pre-implantation genetic testing.
(PGT), more technologies have been developed to enable couples known to be at risk for genetic diseases to avoid passing these diseases on to the next generation [8]. Indeed, these approaches can be used to differentiate affected embryos during in vitro fertilization (IVF) by biopsying embryos to test for structural chromosomal abnormalities and single-gene mutations before implantation [9].

In this review, we present updated genetic screening indications for idiopathic infertility in men, discuss the characteristics of structural chromosomal abnormalities and single-gene mutation diseases, and suggest appropriate treatments for infertility-related diseases caused by genetic abnormalities.

Screening for genetic analysis

1. Updated indications for karyotype analysis

In 2021, the American Urological Association (AUA) and American Society for Reproductive Medicine (ASRM) joined to review the diagnosis and treatment of infertility in men and indicated karyotype analysis for azoospermia or severe oligozoospermia (sperm concentration < 5 million/mL) with elevated follicle-stimulating hormone (FSH) levels, testicular atrophy, or a presumed diagnosis of impaired sperm production as the cause of azoospermia [10]. Additionally, the European Association of Urology (EAU) guidelines state that karyotype analysis should be performed in men with azoospermia or oligozoospermia (sperm concentration < 10 million/mL) and a family history of recurrent spontaneous abortions, malformations, or mental retardation [11]. However, other studies have evaluated these cutoffs and questioned whether there might be more effective thresholds to screen for karyotype abnormalities. For example, Dul et al. [12] investigated the incidence of chromosomal abnormalities and showed that azoospermia occurred in 15.4% of infertile men, whereas 0–1, 1–5, 5–20, and more than 20 million sperm/mL were detected in 3.0%, 2.1%, 2.7%, and 2.9% of cases, respectively. These findings suggest that sperm concentration may not be the most effective threshold for recommending karyotype analysis. Current guidelines for oligozoospermia tend to result in over-testing of patients. Additionally, the newly proposed 2021 AUA/ASRM guidelines include recurrent pregnancy loss (≥2), and European Society of Human Reproduction and Embryology special interest group study for recurrent implantation failure (≥3) during IVF may also be added to these guidelines [10,13].

2. Updated indications for Y-chromosome microdeletion

The AUA, ASRM, and EAU guidelines recommend Y chromosome microdeletion tests for azoospermia or severe oligozoospermia (< 5 million sperm/mL) with elevated FSH or testicular atrophy [10,11].

A recent systematic review and meta-analysis of European and North American studies estimated the prevalence of Y-chromosome microdeletions according to this guideline and noted that the rate of Y-chromosome microdeletions in azoospermia is approximately 8%–12%, whereas those in very severe oligozoospermia (0–1 million sperm/mL), severe oligozoospermia (1–5 million sperm/mL), and sperm concentrations of 5–20 million sperm/mL are approximately 5%, 0.8%, and 0.5%, respectively [14]. These results demonstrate that Y-chromosome microdeletions are much less common than previously estimated in men with more than 1–5 million sperm/mL. In fact, the prevalence of Y-chromosome microdeletions in this population (0.8%) is similar to that for which testing is not recommended (more than 5 million sperm/mL; 0.7%). Newly published data have shown that Y-chromosome microdeletions are rare (i.e., less than 1%); thus, future guidelines may recommend and confirm Y-chromosome microdeletion testing for men when sperm concentrations are less than 1 million sperm/mL (Table 1).

Sex chromosome abnormalities

1. Klinefelter syndrome

Sex chromosome abnormalities occur when there is an error in cell division following mitosis or meiosis. An abnormal number of chromosomes is referred to as aneuploidy, which occurs when one chromosome is missing from a pair (monosomy) or there are more than two chromosomes in a pair (trisomy, tetrasomy, etc.).

<table>
<thead>
<tr>
<th>Genetic thresholds</th>
<th>Current guidelines</th>
<th>New threshold</th>
</tr>
</thead>
<tbody>
<tr>
<td>Karyotype abnormality thresholds</td>
<td>&lt; 5 million sperm/mL</td>
<td>&lt; 5 million sperm/mL</td>
</tr>
<tr>
<td>Y chromosome microdeletion thresholds</td>
<td>&lt; 5 million sperm/mL</td>
<td>&lt; 5 million sperm/mL</td>
</tr>
</tbody>
</table>

AUA, American Urological Association; ASRM, American Society for Reproductive Medicine; EAU, European Association of Urology; NOA, nonobstructive azoospermia.
Klinefelter syndrome is associated with small, firm testes with hyalinization of the seminiferous tubules and failure of spermatogenesis. Patients with this syndrome present with clinical features such as tall stature, slightly decreased intelligence, signs of androgen deficiency, and gynecomastia. The karyotype of patients with Klinefelter syndrome is two or more X chromosomes, with 47,XXY being the most common. Symptoms are more severe if three or more X chromosomes are present (e.g., 48,XXXY or 49,XXXXY) [15]. Semen analysis of patients with 47,XXY Klinefelter syndrome typically reveals azoospermia, whereas mosaic Klinefelter syndrome (46,XY/47,XXY) is typically accompanied by severe oligozoospermia to azoospermia.

In addition to reproductive issues, patients with Klinefelter syndrome also exhibit general health problems, such as metabolic syndrome, autoimmune diseases, and psychiatric diseases [16]. Notably, age is the most important predictive factor for the success rate of m-TESE in patients with Klinefelter syndrome, and the success rate has been shown to be higher in men younger than 31 years of age [17]. PGT of embryos resulting from intracytoplasmic sperm injection (ICSI) using sperm from m-TESE is the treatment of choice for patients with Klinefelter syndrome.

2. 47,XXX

47,XXX (Jacob syndrome) is a type of sex chromosomal abnormality related to the occurrence of parental non-disjunction at meiosis II, resulting in the production of an extra Y chromosome and acquisition of the 47,XXY karyotype in affected offspring [18]. Most men with the 47,XXY karyotype are phenotypically taller than average and are at an increased risk of learning problems. Men with 47,XXX syndrome can have variable sperm counts, ranging from normozoospermia to azoospermia. An increased incidence of chromosomally abnormal spermatozoa in the semen is the result of a random event during sperm development [19]. Patients with this condition may receive speech therapy or require extra help with schoolwork, and many patients with 47,XXX are unaware that they have a sex chromosome abnormality.

3. 46,XX male syndrome

46,XX male syndrome (de la Chapelle syndrome) is rare disease that occurs in 1 in 20,000 newborns [20]. The phenotype includes azoospermia, but is notably different from that of Klinefelter syndrome, including a small stature and higher incidence rates of cryptorchidism and ambiguous genitalia [21]. Translocation of sex-determining region Y on the X chromosome is responsible for up to 90% of cases of 46,XX male syndrome. The gene is located below the pseudoautosomal region of the short arm of the Y chromosome, and abnormal translocation can occur during meiosis [22].

46,XX male syndrome presents as azoospermia with a pathology of Sertoli cell-only syndrome (SCOS) on testis biopsy and a sperm retrieval rate of 0%. Therefore, patients with 46,XX male syndrome should not undergo m-TESE. A careful endocrine assessment, including an analysis of FSH, luteinizing hormone, and testosterone levels, and monitoring are recommended.

**Autosomal abnormalities**

1. Translocation

There are two types of translocations: unbalanced and balanced. Robertsonian translocation is the most common form of unbalanced translocation and is found in 0.9%–3.4% of infertile men [23]. Robertsonian translocations occur when two acrocentric chromosomes break near the centromere, resulting in separation of the long and short arms, and have an incidence of 1:1,000 [24]. The long arms fuse to form one large chromosome, and the short arms fuse to form one small chromosome, which is subsequently lost, resulting in 45 chromosomes [25]. The acrocentric chromosomes in Robertsonian translocations include chromosomes 13, 14, 15, 21, and 22. Carriers of a Robertsonian translocation are phenotypically normal because the lost short arms generally contain nonessential genetic information, resulting in a balanced structural chromosome anomaly [26].

However, this chromosome anomaly can cause meiotic disturbances during spermatogenesis and produce sperm with abnormal genetic material. Owing to the increased rate of unbalanced gametes, patients with Robertsonian translocation are at an increased risk of having aneuploid offspring that can potentially result in miscarriage, congenital anomalies, and babies with trisomy syndromes, such as trisomy 21 (Down syndrome) and trisomy 13 (Patau syndrome). Therefore, these patients should undergo genetic counseling and IVF-ICSI with PGT, which may reduce the miscarriage rate by selecting balanced embryos for implantation during IVF-ICSI [27].

2. Inversion

Paracentric inversions occur when the centromere is not included in the inverted segment, whereas pericentric inversions occur when the centromere is included. Although chromosomal inversion is less common than translocation, inversion has been reported to be 13 times more common in infertile men than in the general male population [28]. The majority of inversion carriers are phenotypically normal; however, some people may have a disease secondary to a breakpoint disrupting a gene [29]. The risk of unbalanced gametes in patients with chromosomal inversion depends on the size and location of the inversion, as well as recombination events. Disruptions in meiosis can lead to spermatogenic failure, thereby resulting in infertility. Therefore, male carriers of chromosome inversions may show various findings in semen analysis, such as azoospermia, oligozo-
ospermia, asthenozoospermia, and normozoospermia.

If unbalanced gametes are produced, genetic counseling should be performed to inform patients of the potential for miscarriage, congenital anomalies, and the transmission of genetic abnormalities, which may affect future male infertility. However, in inversion carriers, the need for PGT is still not clear. Because minimal inversion carriers do not harbor recombinant products, they would not be expected to benefit from PGT. Anton et al. [30] proposed a threshold of greater than 100 Mbp for the size of inverted segments as a possible indication of PGT in patients with chromosomal inversion.

3. Deletions

Large chromosome deletions are the least frequent chromosomal abnormalities in infertile men. Carriers of large chromosome deletions are missing a substantial proportion of genetic material. Large autosomal chromosomal deletions may be life-threatening or could result in significant phenotypic abnormalities owing to developmental delays or specific clinical characteristics, including Prader-Willi syndrome, Angelman syndrome, and Williams-Beuren syndrome [31-33]. The clinical characteristics of chromosomal abnormalities are summarized in Table 2.

4. Y-chromosome microdeletion

The incidence of Y-chromosome microdeletion is 10%–15% in infertile men with NOA or severe oligozoospermia [34]. The Y chromosome contains many genes that are important in spermatogenesis and the development of male gonads [35]. The proposed gene region involved in spermatogenesis related to the Y chromosome is named azoospermia factor (AZF); there are three subtypes (AZFa, AZFb, and AZFc). Phenotypes vary depending on the type of AZF region mutation.

5. AZFa deletions

Deletion of the entire AZFa region results in SCOS and azoospermia [36]. The AZFa region contains two genes: USP9Y and DBY (DDX3Y) [37]. A diagnosis of complete deletion of the AZFa region indicates that retrieval of testicular sperm is not feasible, as the sperm retrieval rate in patients with deletion of the AZFa region is 0%. Therefore, m-TESE is contraindicated in patients with complete AZFa deletion.

6. AZFb deletions

The AZFb region contains two main genes: RBMY and PRY [38,39]. The genes in the AZFb region support the maturity of spermatozoa and are required for the efficient progression of sperm through meiosis into spermiogenesis [40]. The histological phenotype in patients with complete AZFb or AZFb+c deletions shows SCOS or maturation arrest, leading to azoospermia [41]. The chance to retrieve sperm from m-TESE is negligible in cases of AZFb deletion. Therefore, m-TESE is contraindicated in patients with complete AZFb deletion.

<table>
<thead>
<tr>
<th>Table 2. Clinical characteristics of chromosomal abnormalities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chromosome disorder</td>
</tr>
<tr>
<td>Klinefelter syndrome</td>
</tr>
<tr>
<td>Jacob syndrome</td>
</tr>
<tr>
<td>46 XX male syndrome</td>
</tr>
<tr>
<td>Robertsonian translocation</td>
</tr>
<tr>
<td>Balanced reciprocal translocation</td>
</tr>
<tr>
<td>Inversion</td>
</tr>
<tr>
<td>Deletion</td>
</tr>
<tr>
<td>Angelman syndrome</td>
</tr>
<tr>
<td>Williams-Beuren syndrome</td>
</tr>
</tbody>
</table>

TESE, testicular sperm extraction; IVF, in vitro fertilization; ICSI, intracytoplasmic sperm injection; PGT-SR, preimplantation genetic testing-chromosomal structural rearrangement; AID, artificial insemination by donor; OAT, oligoasthenoteratozoospermia; SA, semen analysis.

https://doi.org/10.5653/cerm.2021.04476
7. AZFc deletions

The AZFc region contains DAZ, GOLGA2LY, and CSPG4LY [42]. Complete AZFc deletion presents as various types of impaired spermatogenesis [43]. Men with AZFc deletions related to the DAZ gene exhibit variable phenotypes ranging from complete azoospermia to mild oligozoospermia [44]. In a few cases, men with the AZFc deletion have conceived multiple children naturally; however, all of the sons of these men have been found to be infertile [45].

Follow-up studies of patients with AZFc deletions have shown that AZFc microdeletions are associated with a progressive decline in sperm concentration and progression of patients from oligozoospermia to azoospermia [46]. These findings suggest that AZFc deletions could further affect spermatogenesis and worsen the overall sperm quality. Therefore, for men with AZFc deletions who have sperm in the semen, samples should be cryopreserved to prevent possible m-TESE in the future. In 2003, Hoppes et al. [47] reported a high sperm retrieval rate (75%) in patients with AZFc deletion. m-TESE could be recommended for patients with AZFc deletion, although patients should be informed of the possibility that the deletion may be inherited in their sons.

8. AZFc partial deletions

The influence of partial deletions on spermatogenesis is still unclear. None of the currently identified AZFc partial deletions completely eliminate any gene family; however, some have been shown to reduce the copy number of genes. The most clinically relevant AZFc partial deletion is the gr/gr deletion, which removes nearly half of the genes present in the AZFc region and therefore affects the dosage of multicopy genes, such as DAZ, CDY1, and BPY2, in this region [48]. Men with this deletion are at a significantly increased risk for oligozoospermia [49].

Importantly, the effects of AZFc partial deletions on patients’ fertility largely reflect ethnic diversity in spermatogenesis. The reason for these differences is unclear, but they may be related to Y haplogroups and deletion subtypes. This may be clinically relevant because this type of deletion could contribute to the etiology of impaired spermatogenesis. Furthermore, couples should be informed that AZFc partial deletion will be transmitted to their sons and could become complete AZFc deletion in the next generation of male offspring [50].

Single-gene mutations related with abnormal sperm count in spermatogenesis

1. Testis-expressed gene 11 (TEX11)

TEX11 is an X-linked meiosis-specific gene that has been found to be essential for spermatogenesis in humans with a phenotype of NOA [51]. The prevalence of TEX11 mutation in men presenting with NOA is 2.4% but can be as high as 15% when specifically considering men with NOA showing no meiotic arrest with SCOS [52]. The identification of TEX11 can be useful in the diagnostic process and genetic counseling of patients with NOA.

2. Testis expressed gene 15 (TEX15)

TEX15 encodes a testis-specific protein that repairs DNA double-stranded breaks [53]. An analysis of testicular histopathology revealed maturation arrest at the primary spermatocyte stage. The TEX15 gene is currently believed to be responsible for spermatogenesis failure.

3. DEAD-box helicase 3 Y-linked (DDX3Y)

DDX3Y encodes a conserved RNA DDX3 helicase specifically expressed in pre-meiotic spermatogonial cells [54]. This gene is mapped within the AZFα region, and deletion of this region causes SCOS. DDX3Y expression is required for human fetal germ-cell proliferation, and DDX3Y deletions have been identified in patients with SCOS or severe hypospermatogenesis [55].

4. Nuclear receptor subfamily 5 group A member 1 (NRSA1)

Among a cohort of infertile patients, NRSA1 mutations were identified in 3.9% of those with azoospermia or cryptozoospermia and in 4.3% of those with severe oligozoospermia [56]. Based on histological analyses, NRSA1 mutations result in SCOS, severe hypospermatogenesis, or partial spermatocyte arrest in patients with NOA.

5. Heat shock factor 2 (HSF2)

HSF2 encodes a protein belonging to the HSF family, which activates target genes under stress conditions. In humans, three synonymous mutations and mutations in HSF2 have been identified in cases of azoospermia with maturation arrest at the spermatocyte stage [57].

6. Doublesex and Mab-3 related transcription factor 1 (DMRT1)

DMRT1 encodes a testis-specific transcription factor that plays a role in testis differentiation. Deletion of chromosome 9p, which includes DMRT1, is known to be associated with 9p deletion syndrome and XY gonadal dysgenesis [58]. Smaller deletions and mutations of this gene have been identified in patients with NOA without XY gonadal dysgenesis [59].

Single-gene mutations related to abnormal sperm motility in spermiogenesis

1. Multiple morphological abnormalities of the sperm flagella and primary ciliary dyskinesia

Multiple morphological abnormalities of the sperm flagella
Single-gene mutations related to abnormal sperm morphology in spermiogenesis

1. Globozoospermia

Globozoospermia is rare, affecting 0.1% of infertile men, and is characterized by round-headed sperm with few acrosomes, which are unable to fertilize oocytes owing to the lack of an acrosome reaction. Mutations in four genes (DPY19L2, ZPBP, PICK1, and SPATA16) have been shown to be associated with globozoospermia [65].

The most commonly observed genetic defects in patients with globozoospermia are in the DPY19L2 gene. The gene product of DPY19L2 is involved in elongation and acrosome formation [66]. The only fertility option in patients with 100% globozoospermia is IVF-ICSI. Because a lack of acrosome phospholipase is related to oocyte activation, artificial oocyte activation with calcium ionophores or electric activation has been proposed for the treatment of patients with complete globozoospermia. Importantly, men with globozoospermia exhibit high rates of sperm aneuploidy and DNA damage, and couples show low pregnancy rates. Screening for the DPY19L2 gene can be considered as a helpful strategy for men with globozoospermia in order to improve the IVF-ICSI and PGT results and family counseling.

2. Macrozoospermia

Macrozoospermia is characterized by large-headed and multi-flagellated spermatozoa. Mutations in AURKC have been shown to be the main genetic cause of sperm macrocephaly, resulting in alterations in meiotic division and tetraploid spermatozoa if both meiotic divisions are affected. Genetic screening of the AURKC gene could reasonably be performed for patients whose sperm contains 30% or more of large-headed spermatozoa. If a mutation is identified, IVF-ICSI is contraindicated because the macroscopic selection of spermatozoa combined with fluorescence in situ hybridization analysis and flow cytometry does not enable a correlation between sperm morphology and the genetic content of the nucleus. IVF-ICSI is not contraindicated in patients without mutations, and PGT can be recommended for those with intermediate aneuploid spermatozoa. The genes related to spermatogenesis and spermiogenesis are listed in Table 3 and Figure 1.

Treatment of infertile men with chromosomal and genetic abnormalities

1. Clomiphene citrate

Clomiphene citrate has also shown efficacy when administered prior to m-TESE. An improvement in m-TESE was demonstrated by Hussein et al. [67], who reported that patients receiving therapy with clomiphene citrate had a 20%–25% greater chance of having sperm identified in m-TESE than those not receiving any adjuvant treatment. Clomiphene citrate is generally well-tolerated, and common side effects include gastrointestinal distress, hair loss, gynecomastia, and weight gain. Visual disturbances, such as blurred vision and diplopia, occur in 1.5% of patients [68].

2. Aromatase inhibitors

Aromatase is a cytochrome P450 enzyme that irreversibly converts androgens to estrogens in various tissues, including the testis, liver, brain, and adipose tissue [69]. Aromatase inhibitors can be used in NOA to address the imbalances in testosterone and estrogen levels that affect spermatogenesis. Aromatase inhibitors can selectively increase endogenous testosterone levels without increasing estrogens [70]. The effects of aromatase inhibitors on spermatogenesis have also been investigated. Patients with NOA may be prescribed 2.5 mg of letrozole daily for 4 months, which can convert hypospermatogenesis to normal spermatogenesis, as demonstrated by testis biopsy [71].

3. m-TESE

m-TESE can be used for treatment for NOA with or without genetic diseases, such as Klinefelter syndrome, 47XXY, and AZFc deletions. The contraindications for m-TESE are 46,XX male syndrome and AZFa or AZFb deletions. In those cases, hormone replacement and m-TESE should be absolutely avoided.
Table 3. Genes related to the failure of human spermatogenesis and spermiogenesis

<table>
<thead>
<tr>
<th>Gene</th>
<th>Full name</th>
<th>Phenotype</th>
<th>HUGO gene nomenclature ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>TEX11</td>
<td>Testis expressed gene 11</td>
<td>Spermatocyte maturation arrest</td>
<td>HGNC: 11733</td>
</tr>
<tr>
<td>TEX15</td>
<td>Testis expressed gene 15</td>
<td>Non-obstructive azoospermia</td>
<td>HGNC: 11738</td>
</tr>
<tr>
<td>DDX3Y</td>
<td>DEAD-box helicase 3 Y-linked</td>
<td>Spermatocyte maturation arrest</td>
<td>HGNC: 2699</td>
</tr>
<tr>
<td>NR5A1</td>
<td>Nuclear receptor subfamily 5 group A member 1</td>
<td>Spermatocyte maturation arrest</td>
<td>HGNC: 7983</td>
</tr>
<tr>
<td>HSF2</td>
<td>Heat shock factor protein 2</td>
<td>Spermatocyte maturation arrest</td>
<td>HGNC: 5225</td>
</tr>
<tr>
<td>DMRT1</td>
<td>Doublesex and mab-3 related transcription factor 1</td>
<td>Non-obstructive azoospermia</td>
<td>HGNC: 2934</td>
</tr>
<tr>
<td>DNAI1</td>
<td>Dynein axonemal intermediate chain 1</td>
<td>Asthenozoospermia</td>
<td>HGNC: 2940</td>
</tr>
<tr>
<td>DNAH5</td>
<td>Dynein axonemal heavy chain 5</td>
<td>Asthenozoospermia</td>
<td>HGNC: 2954</td>
</tr>
<tr>
<td>DPY19L2</td>
<td>Dpy-19 like 2</td>
<td>Globozoospermia</td>
<td>HGNC: 19414</td>
</tr>
<tr>
<td>ZPBP</td>
<td>Zona pellucida-binding protein 1</td>
<td>Globozoospermia</td>
<td>HGNC: 15662</td>
</tr>
<tr>
<td>PICK1</td>
<td>Protein interacting with c kinase–1</td>
<td>Globozoospermia</td>
<td>HGNC: 9394</td>
</tr>
<tr>
<td>SPATA16</td>
<td>Spermatogenesis-associated protein 16</td>
<td>Globozoospermia</td>
<td>HGNC: 29935</td>
</tr>
<tr>
<td>AURKC</td>
<td>Aurora kinase C</td>
<td>Macrozoospermia</td>
<td>HGNC: 11391</td>
</tr>
</tbody>
</table>

HUGO, Human Genome Organisation; HGNC, HUGO Gene Nomenclature Committee.

Figure 1. Biological overview of the genetic factors involved in human spermatogenesis and spermiogenesis. DDX3Y, DEAD-box helicase 3 Y-linked; DMRT1, dynein intermediate chain 1, axonemal; TEX11, testis expressed gene 11; TEX15, testis expressed gene 15; HSF2, heat shock factor protein 2; NR5A1, nuclear receptor subfamily 5 group A member 1; DNAI1, dynein intermediate chain 1, axonemal; DNAH5, dynein intermediate chain 5, axonemal; DPY19L2, Dpy-19 like 2; ZPBP, zona pellucida-binding protein 1; PICK1, protein interacting with C kinase–1; SPATA16, spermatogenesis-associated protein 16; AURKC, aurora kinase C. By courtesy of Encyclopaedia Britannica, Inc., copyright 2011; used with permission.
4. Hormone replacement pretreatment before m-TESE

Positive results have been demonstrated for the use of human chorionic gonadotropin (HCG) hormonal injections in patients with NOA undergoing sperm retrieval in a second round of m-TESE. Shirazi et al. [72] studied therapy with 5,000 IU of HCG three times weekly for 3 months in patients who were previously shown to lack sperm after m-TESE. HCG treatment significantly increased the rate of sperm retrieval at the time of the second round of m-TESE compared with men who did not receive HCG treatment. The sperm retrieval rate was 21% in patients who had undergone HCG treatment. However, no sperm was retrieved in the untreated group [72]. Despite these findings, the results remain inconsistent. For example, in a study of non-mosaic Klinefelter syndrome, Ramasamy et al. [73] found that the sperm retrieval rate during m-TESE did not depend on the preoperative administration of HCG. Additionally, preoperative testosterone levels were found to be a significant predictive factor for the sperm retrieval rate. Patients with testosterone levels greater than or equal to 250 ng/dL had a 22% higher sperm retrieval rate than patients with testosterone levels less than 250 ng/dL.

IVF-ICSI with PGT for chromosomal structural rearrangement

The first report on children born after PGT was published in 1990 by Handside et al. [74], who described the use of polymerase chain reaction to detect repetitive Y-sequences for sex determination in families with X-linked diseases. PGT evolved from an experimental procedure in the early 1990s as an alternative to a well-established clinical procedure. Numerous technical advances in the field of single-cell genetic testing and assisted reproduction have led to extensive changes in PGT practice.

PGT involves the biopsy of a single or few cells from in vitro fertilized oocytes or embryos and testing of the biopsied cells for genetic abnormalities [75]. The selective transfer of embryos unaffected by the study conditions offers the advantages of circumventing an invasive prenatal diagnosis and possible therapeutic termination of pregnancy.

PGT for chromosomal structural rearrangement (PGT-SR) is appropriate for patients with chromosome rearrangements and those who are at risk of creating embryos with an incorrect chromosome number or structure. The indications for PGT-SR include sex chromosome abnormalities and an incorrect chromosome number or structure. (47,XXY Klinefelter syndrome, 47,XY Stein syndrome, reciprocal translocation, Robertsonian translocation, or inversion). Many carriers of balanced chromosome rearrangements are healthy and unaware of their carrier status until they try to have children. Carriers of balanced rearrangements are at risk for producing embryos with the incorrect amount of chromosomal material, which typically do not lead to a successful pregnancy. PGT-SR can help identify embryos with the correct amount of chromosomal material that are most likely to lead to a successful pregnancy and healthy live birth.

Reciprocal translocations occur when pieces of genetic material break off from two different chromosomes and swap places. People that carry a balanced translocation can create embryos that have either the same balanced translocation, the unbalanced form of the translocation where there is a gain or loss of chromosomal material, or a completely normal set of chromosomes. If one parent is a carrier of a reciprocal translocation, approximately 80% of the resulting embryos will contain an incorrect amount of genetic material.

Robertsonian translocations occur when two chromosomes join together to form one large chromosome, giving an overall chromosome count of 45 instead of 46. Inversions are chromosome rearrangements that involve only one chromosome. In an inversion, a segment of a chromosome is flipped and reinserted upside down. People with an inversion may create embryos with missing or duplicated segments of chromosomes.

IVF-ICSI and PGT for monogenic disorders

PGT for monogenic disorders (PGT-M) is an increasingly popular technology that allows couples affected by or known to be at risk for a genetic disease to avoid passing on the condition to the next generation. It is used in conjunction with IVF, after which the embryos are biopsied to test for the specific gene mutation before implantation and pregnancy.

Common indications for PGT-M include cystic fibrosis, spinal muscular atrophy, hereditary hemoglobinopathies, and Huntington disease; however, its indications are rapidly expanding in the post-human genome sequencing era. The transmission of genetic urological disorders, such as Alport syndrome, autosomal dominant polycystic kidney disease, and Von Hippel-Lindau syndrome, could also be prevented by IVF-ICSI and PGT-M [76,77]. Many single-gene mutations linked with spermatogenesis (e.g., mutations in X-linked, Y-linked, and autosomal genes) could be detected by PGT-M, enabling the prevention of disease complications (Table 3).

Conclusion

Previously, karyotype analyses and Y-chromosome microdeletion tests were used as effective techniques for detecting the etiology of azoospermia or severe oligozoospermia. However, in recent years, the indications for these tests have been revised to include abnormalities in X-linked and autosomal genes related to genetic infertility, as well as sex chromosome abnormalities and Y-chromosome ab-
normalities. Male infertility related to impaired spermatogenesis is associated with multiple factors and exhibits genetic heterogeneity, and it is necessary to identify additional candidate genes that may be related to male infertility.

With rapid advances in genetic diagnostic tools, such as next-generation sequencing, single genes related to azoospermia, cryptozoospermia, asthenozoospermia, and specific morphological abnormalities have been identified, resulting in a decrease in “idiopathic” male infertility. Personalized hormonal treatment, genetic counseling, and IVF-ICSI with PGT could prevent the transmission of genetic disorders and enable the implantation of normal embryos, thereby improving pregnancy rates in infertile men with genetic diseases. Additionally, cost-benefit analyses of genetic studies should be investigated in future research.

Conflict of interest

No potential conflict of interest relevant to this article was reported.

ORCID

Seung Ryool Lee https://orcid.org/0000-0002-9959-3488
Tae Ho Lee https://orcid.org/0000-0002-6797-1042
Seung-Hun Song https://orcid.org/0000-0003-4649-9129
Dong Suk Kim https://orcid.org/0000-0001-7350-0303
Kyung Hwa Choi https://orcid.org/0000-0001-9421-9596
Jae Ho Lee https://orcid.org/0000-0001-7750-6032
Dae Keun Kim https://orcid.org/0000-0003-3237-6304

Author contributions

Conceptualization: SHS. Formal analysis: DSK, SRL. Data curation: KHC. Project administration: JHL. Investigation: THL, DKK. Writing–review & editing: SRL, DKK. Writing–original draft: DKK, THL. Writing–review & editing: SRL, DKK. References

18. Wong EC, Ferguson KA, Chow V, Ma S. Sperm aneuploidy and


47. Hopps CV, Mielenk A, Goldstein M, Palermo GD, Rosenwaks Z.


74. Handyside AH, Kontogianni EH, Hardy K, Winston RM. Pregnan-
cies from biopsied human preimplantation embryos sexed by
75. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, de Mou-
zon J, Sokol R, et al. The International Glossary on Infertility and
76. Snoek R, Stokman MF, Lichtenbelt KD, van Tilborg TC, Simcox CE,
Paulussen AD, et al. Preimplantation genetic testing for mono-
77. Obradors A, Fernandez E, Rius M, Oliver-Bonet M, Martinez-Fresno
M, Benet J, et al. Outcome of twin babies free of Von Hipp-
pel-Lindau disease after a double-factor preimplantation genetic
diagnosis: monogenic mutation analysis and comprehensive